

# Dupixent (dupilumab)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	<p>Asthma: Initial: 6 months Continuation: 1 year</p> <p>Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): Initial: 6 months Continuation: 1 year</p> <p>Chronic Obstructive Pulmonary Disease (COPD) Initial: 6 months Continuation: 12 months</p> <p>Chronic Spontaneous Urticaria (CSU) Initial: 6 months Continuation: 12 months</p> <p>All other diagnoses: 1 year</p>

Medications	Quantity Limit
Dupixent (dupilumab) 100 mg/0.67 mL syringe	2 syringes per 28 days
Dupixent (dupilumab) 200 mg/1.14 mL pre-filled syringe/pen*	<ul style="list-style-type: none"> <li>11 years old or younger: 1 syringe/pen every 28 days<sup>@^</sup></li> <li>12 years old or older: 2 syringes/pens every 28 days</li> </ul>
Dupixent (dupilumab) 300 mg/2 mL pre-filled syringe, 300 mg/2mL pre-filled pen*	<ul style="list-style-type: none"> <li>11 years old or younger: 1 syringe/pen per 28 days<sup>%+</sup></li> <li>12 years old or older: 2 syringes/pens per 28 days<sup>#</sup></li> </ul>

\*Initiation of therapy: May approve two additional 200 mg/1.14 mL OR 300 mg/2 mL pre-filled syringes/pens in the first month of therapy for initiation dose for the indication of atopic dermatitis if the individual is 6 years old or older OR asthma if the individual is 12 years old or older OR prurigo nodularis OR chronic spontaneous urticaria OR bullous pemphigoid.

@For individuals weighing 30kg or more, may approve 2 syringes/pens per 28 days.

- % For individuals more than 30 kg, may approve 2 syringes/pens per 28 days.  
^ In the treatment of eosinophilic esophagitis: May approve 2 syringes/pens per 28 days.  
# In the treatment of eosinophilic esophagitis: May approve 4 syringes/pens per 28 days.  
+ In the treatment of eosinophilic esophagitis for individuals weighing 40 kg or more: May approve 4 syringes/pens per 28 days.

## **APPROVAL CRITERIA**

Initial requests for Dupixent (dupilumab) for the treatment of asthma may be approved if the following criteria are met:

- I. Individual is 6 years of age or older; **AND**
  - II. Individual has a diagnosis of moderate-to-severe asthma as demonstrated by the following (NHLBI 2020):
    - A. A pretreatment forced expiratory volume in 1 second (FEV<sub>1</sub>) less than or equal to ( $\leq$ ) 80% predicted; **AND**
    - B. FEV<sub>1</sub> reversibility of at least 12% and 200 milliliters (ml) after albuterol (salbutamol) administration; **AND**
  - III. One of the following:
    - A. Documentation is provided that individual has a blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 150 cells/microliter [1 microliter ( $\mu$ L) is equal to 1 cubic millimeter ( $\text{mm}^3$ )] at initiation of therapy; **AND**
    - B. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high dose inhaled corticosteroids plus long acting beta<sub>2</sub> –agonists, leukotriene modifiers, theophylline or oral corticosteroids) (ERS/ATS 2013, GINA 2022);
- OR**
- C. Individual has oral corticosteroid dependent asthma; **AND**
  - D. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to high dose inhaled corticosteroid with daily oral glucocorticoids given in combination with a controller medication (either a long-acting beta<sub>2</sub>-agonist, **or** leukotriene receptor antagonist, **or** theophylline) (ERS/ATS 2013, GINA 2022);

## **AND**

- IV. Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of a systemic corticosteroid **or** temporary increase in the individual's usual maintenance dosage of oral corticosteroids (Castro 2018, Rabe 2018).

Continuation of therapy with Dupixent (dupilumab) for asthma may be approved if the following criteria are met:

- I. Individual has experienced one or more of the following:
  - A. Decreased utilization of reliever medications; **OR**
  - B. Decreased frequency of exacerbations (defined as worsening of asthma that requires an increase in inhaled corticosteroid dose or treatment with systemic corticosteroids); **OR**
  - C. Increase in predicted FEV<sub>1</sub> from pretreatment baseline; **OR**
  - D. Reduction in reported asthma-related symptoms, such as, asthmatic symptoms upon awakening, coughing, fatigue, shortness of breath, sleep disturbance, or wheezing; **AND**
  - E. Individual continues to use Dupixent in combination with inhaled corticosteroid-based controller therapy.

Initial requests for Dupixent (dupilumab) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype; **AND**
- III. Documentation is provided that individual has a blood eosinophil count of at least 300 per microliter (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) (Bhatt 2023); **AND**
- IV. COPD diagnosis is demonstrated by post-bronchodilator FEV<sub>1</sub>/FVC <0.7 (Bhatt 2023); **AND**
- V. Individual has moderate to severe airflow obstruction demonstrated by post-bronchodilator FEV<sub>1</sub> 30-70% predicted normal value (Bhatt 2023); **AND**
- V. Individual meets one of the following (Bhatt 2023) (A or B):
  - A. At least one (1) hospitalization or more than 24 hours of medical observation related to COPD in the past twelve (12) months; **OR**
  - B. In the past twelve (12) months, at least two (2) moderate COPD exacerbations and required systemic steroids for at least one (1) exacerbation with or without antibiotics; **AND**
- VI. Documentation is provided that individual meets one of the following (Bhatt 2023) (A or B):
  - A. Individual is on a stable dose of LAMA-LABA therapy including inhaled glucocorticoid; **OR**
  - B. Individual is unable to use an inhaled glucocorticoid due to a medical reason and is on a stable dose of LAMA-LABA therapy

Continuation requests for Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease (COPD) may be if approved if the following criteria are met:

- I. Individual will continue to use Dupixent (dupilumab) in combination with LAMA/LABA therapy OR ICS/LAMA/LABA therapy; **AND**
- II. Treatment with Dupixent has resulted in clinical improvement in one or more of the following:
  - A. Decreased utilization of reliever medication; **OR**
  - B. Decreased frequency or severity of exacerbations; **OR**
  - C. Increase in percent predicted FEV1 from pretreatment baseline; **OR**
  - D. Reduction in reported COPD-related symptoms, including shortness of breath, cough, fatigue or sleep disturbance.

Initial requests for Dupixent (dupilumab) for the treatment of atopic dermatitis may be approved when the following criteria are met:

- I. Individual is 6 months or older; **AND**
- II. Individual has a diagnosis of moderate to severe atopic dermatitis; **AND**
- III. Documentation is provided that individual has tried one of the following, and treatment failed to achieve and maintain remission of low or mild disease activity:
  - A. Topical calcineurin inhibitors;  
**OR**
  - B. Eucrisa;  
**OR**
  - C. Opzelura;  
**OR**
  - D. Zoryve 0.15% Cream;  
**OR**
  - E. Vtama Cream;  
**OR**
  - F. Phototherapy (UVB or PUVA);  
**OR**
  - G. Non-corticosteroid systemic immunosuppressants (such as cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil);  
**OR**
  - H. Individual has contraindications to topical calcineurin inhibitors **AND** Eucrisa **AND** Opzelura **AND** Zoryve 0.15% Cream **AND** Vtama cream **AND** Non-corticosteroid systemic immunosuppressants (such as cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil) **AND** unable to use phototherapy.

Continuation requests for Dupixent (dupilumab) for atopic dermatitis may be if approved if the following criterion is met:

- I. Treatment with Dupixent has resulted in significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decrease in

affected body surface area, pruritus, or severity of inflammation, and/or improved quality of life).

Initial requests for Dupixent (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) may be approved if the following criteria are met:

- I. Individual is age 12 years and older; **AND**
- II. Documentation is provided that individual has a diagnosis of CRSwNP demonstrated on one of the following (AAO-HNSF 2015):
  - A. Anterior rhinoscopy; **OR**
  - B. Nasal endoscopy; **OR**
  - C. Computed tomography (CT); **AND**
- III. Individual has had recent trial and inadequate response to maintenance intranasal corticosteroids (AAO-HNSF 2015); **AND**
- IV. Individual has had a trial and inadequate response or intolerance to one of the following agents (A or B) or has contraindications to all of the following agents (both A and B) (Bachert 2019):
  - A. Systemic corticosteroids; **OR**
  - B. Sino-nasal surgery; **AND**
- V. Individual is requesting Dupixent (dupilumab) as add-on therapy to maintenance intranasal corticosteroids.

Continuation requests for Dupixent (dupilumab) for chronic rhinosinusitis with nasal polyposis (CRSwNP) may be if approved if the following criterion is met:

- I. Treatment with Dupixent has resulted in clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in nasal polyp score or nasal congestion score); **AND**
- II. Individual continues to use Dupixent in combination with maintenance intranasal corticosteroids.

Initial requests for Dupixent (dupilumab) for the treatment of eosinophilic esophagitis (EoE) may be approved if the following criteria are met:

- I. Individual is 1 year of age or older and weighs at least 15 kg; **AND**
- II. Individual has a diagnosis of EoE; **AND**
- III. Documentation is provided that individual has 15 or more intraepithelial eosinophils per high-power field (eos/hpf) (Rothenberg 2023); **AND**
- IV. Documentation is provided that individual has symptoms of dysphagia (Rothenberg 2023); **AND**
- V. Individual has had a trial and inadequate response or intolerance to a course of proton pump inhibitors (PPIs) (AGA 2020, ACG 2025); **AND**

- VI. Individual has had a trial and inadequate response or intolerance to a course of glucocorticoids (including but not limited to fluticasone propionate metered dose inhaler swallowed instead of inhaled, or budesonide inhalation swallowed instead of inhaled) for the treatment of EoE (AGA 2020, ACG 2025)

Continuation requests for Dupixent (dupilumab) for EoE may be if approved if the following criteria is met:

- I. Treatment with Dupixent has resulted in clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in symptoms of dysphagia).

Initial requests for Dupixent (dupilumab) for the treatment of Prurigo Nodularis (PN) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of PN; **AND**
- III. Individual has 20 or more PN lesions (Yosipovitch 2023); **AND**
- IV. Documentation is provided that individual has tried one of the following and treatment failed to achieve and maintain remission of low or mild disease activity:
  - A. Medium to super-potent topical corticosteroids (Yosipovitch 2023);**OR**
  - B. Topical calcineurin inhibitors (Ständer 2020).

Continuation requests for Dupixent (dupilumab) for PN may be if approved if the following criteria is met:

- I. Treatment with Dupixent has resulted in clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement of symptoms such as decreased itching, or decreased number or thickness of PN lesions).

Initial requests for Dupixent (dupilumab) for the treatment of Bullous Pemphigoid (BP) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of BP; **AND**
- III. Documentation is provided that individual has had a trial and inadequate response or intolerance to high-potency topical corticosteroids or systemic corticosteroids (Borradori 2022); **AND**
- IV. Dupixent is initiated with a tapering course of oral corticosteroids.

Continuation requests for Dupixent (dupilumab) for BP may be if approved if the following criteria is met:

- I. Treatment with Dupixent has resulted in clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decreased itching or improvement of BP lesions).

Initial requests for Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of chronic spontaneous urticaria (CSU); **AND**
- III. Individual has had an inadequate response to a two-week trial of a second generation H1 antihistamine up dosed to a maximum of four times the approved dose (Zuberbier 2022).

Continuation requests for Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) may be approved if the following criterion is met:

- I. Treatment with Dupixent has resulted in clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to itch severity and hive count); **AND**
- II. Individual continues to use Dupixent in combination with second generation H1 antihistamine therapy.

Dupixent (dupilumab) may not be approved for the following:

- I. In combination with oral or topical JAK inhibitors; **OR**
- II. In combination with other immunosuppressants (such as cyclosporine, azathioprine, mycophenolate mofetil, or methotrexate); **OR**
- III. In combination with ensifentrine, depemokimab, tralokinumab, reslizumab, benralizumab, lebrikizumab-, nemolizumab, mepolizumab, tezepelumab, or omalizumab; **OR**
- IV. Individual is requesting Dupixent for the treatment of asthma; **AND**
  - A. Individual has current blood eosinophils greater than 1500 cells/microliter [1 microliter ( $\mu\text{L}$ ) is equal to 1 cubic millimeter ( $\text{mm}^3$ )] (GINA 2022); **AND**
  - B. Asthma related causes have been excluded (GINA 2022);

**OR**

- V. Requests for Dupixent (dupilumab) may not be approved when the above criteria are not met and for all other indications.

**Key References:**

1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet* 2019; 394(10209): 1638-1650.
2. Bhatt, Surya P et al. "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts." *The New England journal of medicine* vol. 389,3 (2023): 205-214. doi:10.1056/NEJMoa2303951.

3. Bhatt, Surya P et al. "Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation." *The New England journal of medicine* vol. 390,24 (2024): 2274-2283. doi:10.1056/NEJMoa2401304.
4. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet*. 2017; 389(10086):2287-2303.
5. Borradori, L., Van Beek, N., Feliciani, C., et al. (2022), Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). *J Eur Acad Dermatol Venereol*, 36: 1689-1704.
6. Castro M, Corren J, Pavord J, et al. Dupilumab efficacy and safety in moderate to severe asthma. *New Engl J Med*. 2018; 378: 2486-96.
7. Chung KF, Wenzel SE, Brozek JL, et.al. International European Respiratory Society/American Thoracic Society guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014; 43(2):343-373.
8. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
9. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. *J Am Acad Dermatol*. 2024;90(2):e43-e56. doi:10.1016/j.jaad.2023.08.102.
10. Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: Guidelines of care for the management of atopic dermatitis in adults. *J Am Acad Dermatol*. 2025 Jun 17:S0190-9622(25)02125-5. doi: 10.1016/j.jaad.2025.05.1386.
11. Dellon ES; Muir AB; Katzka DA; et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. *The American Journal of Gastroenterology* 120(1):p 31-59, January 2025. DOI: 10.14309/ajg.0000000000003194.
12. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. *N Engl J Med*. 2022 Dec 22;387(25):2317-2330. doi: 10.1056/NEJMoa2205982.
13. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
14. Eichenfield L. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *Journal of the American Academy of Dermatology*. 2014-01;71:116.
15. Elmariah, Sarina et al. "Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus." *Journal of the American Academy of Dermatology* vol. 84,3 (2021): 747-760. doi:10.1016/j.jaad.2020.07.025
16. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025. Available from: <http://goldcopd.org>. Accessed on: July 23, 2025.
17. Cloutier MM, Baptist AP, Blake KV, et al; Expert Panel Working Group of the National Heart, Lung, and Blood Institute administered and coordinated National Asthma Education and Prevention Program Coordinating Committee; 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group [published correction appears in *J Allergy Clin Immunol*. 2021;147(4):1528–1530]. *J Allergy Clin Immunol*. 2020;146(6):1217-1270. Available from: <https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates>. Accessed June 22, 2022.
18. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2024. Updated May 2024. Available at: [https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24\\_05\\_22\\_WMS.pdf](https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf)
19. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2025; Updated periodically.
20. Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. *Ann Allergy Asthma Immunol*. 2020;124(5):416-423. doi:10.1016/j.anai.2020.03.020. Accessed on: June 22, 2022
21. Maurer, Marcus et al. "Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials." *The Journal of allergy and clinical immunology* vol. 154,1 (2024): 184-194. doi:10.1016/j.jaci.2024.01.028
22. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *New Engl J Med*. 2018; 378:2475-85.
23. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *American College of Allergy, Asthma & Immunology*. 2014;113:347-385. Accessed July 12, 2021.
24. Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification, and terminology of chronic prurigo. *J Eur Acad Dermatol Venereol*. 2018;32(7):1059-1065. doi:10.1111/jdv.14570.
25. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et.al. American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guideline (Update): Adult Sinusitis. *Otolaryngology-Head and Neck Surgery*. 2015;152(2S)S1-S39. Accessed July 12, 2021.
26. Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Gastroenterol Hepatol*. 2023 Nov;8(11):990-1004. doi: 10.1016/S2468-1253(23)00204-2.

27. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies, *Journal of the American Academy of Dermatology* (2023), doi: <https://doi.org/10.1016/j.jaad.2022.12.029>.
28. Ständer, Sonja et al. (2020). IFSI-guideline on chronic prurigo including prurigo nodularis. *Itch*. 5. e42-e42. 10.1097/itx.0000000000000042. Stevens WW, Schleimer RP, Kern RC. Chronic Rhinosinusitis with Nasal Polyps. *J Allergy Clin Immunol Pract*. 2016;4(4):565-572. doi:10.1016/j.jaip.2016.04.012. Accessed June 22, 2022.
29. Ständer, Sonja et al. IFSI-guideline on chronic prurigo including prurigo nodularis. *Itch* 5(4):p e42, October-December 2020. | DOI: 10.1097/itx.0000000000000042
30. Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies are Not Advisable (PRIME2). *ClinicalTrials.gov* identifier: NCT04202679. Updated September 28, 2022. Accessed October 7, 2022. <https://clinicaltrials.gov/ct2/show/NCT04202679>
31. Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies are Not Advisable (LIBERTY-PN PRIME). *ClinicalTrials.gov* identifier: NCT04183335. Updated September 28, 2022. Accessed October 7, 2022. <https://clinicaltrials.gov/ct2/show/record/NCT04183335>
32. Wenzel S. Treatment of severe asthma in adolescents and adults. Last updated: October 21, 2022. In: *UpToDate*, Post TW (Ed), *UpToDate*, Waltham, MA. Accessed: January 27, 2023.
33. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium to high dose inhaled corticosteroids plus a long-acting Beta-2 agonist: a randomized double-blind, placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet*. 2016; 388:31-44.
34. Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. *Nat Med*. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9.
35. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA<sup>2</sup>LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy*. 2022; 77: 734–766. doi:10.1111/all.15090

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.